- Meeting abstract
- Open Access
Could one splicing-site single nucleotide polymorphism cause the MODY2 disease?
© Mota et al. 2015
- Published: 11 November 2015
- Splice Site
- Amplicon Sequencing
- Single Gene Mutation
- Blood Extraction
- Blast Tool
Maturity-onset Diabetes of the Young (MODY; OMIM# 606391) is often related to a single gene mutation and characterized by dominant inheritance and non-insulin-dependent DM with a young age at diagnosis (Fajans et al., 2001). The most frequent subtype, MODY2, Results from SNPs in the glucokinase gene (Osback et al., 2009). Mapped to human chromosome 7p15.3-p15.1, the GCK gene consists of 10 exons and roughly 45 Kb. More than 600 SNPs were reported to this gene and among those, around 200 are related to the disease (Osback et al., 2009).
We propose screening the GCK gene by DNA sequencing from one 83-year-old volunteer with a MODY2 diagnostic hypothesis.
Informed consent (IC) was obtained and the study was approved by the ethics committee from our institution (CAAE: 40094114.0.0000.5016/License 923.744). The total DNA was extracted using a standard protocol to the blood extraction (PuriLink® Genomic DNA Kit-InvitrogenTM by Thermo). The primers used in this study were adapted from Mota and colleagues (2011). The PCR was performed by Go®Taq Flexi DNA Polymerase kit (Promega) following the manufacturer's instructions. The amplicons sequencing was carried out using the Big Dye® Terminator v3.1 Cycle Sequencing (Applied BiosystemsTM by Life Technologies) and determined in an ABI 3500XL instrument (Applied BiosystemsTM). The sequences were analyzed using Lasergene® SeqMan ProTM for MacOs, version 11.2.1 (DNASTAR®) and were compared with the GenBank human genomic plus transcript database using the BLAST tool (Zhang et al., 2000).
In this study we reported one new mutation within the splicing site, downstream to the exon 6 of the GCK gene. In the future perspectives we will investigate whether this mutation is or not related to the MODY2 disease.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.